Core Viewpoint - The company has announced its financial results for the third quarter of 2025, including a plan for asset impairment provisions and a cash dividend distribution to shareholders [14][24]. Financial Data - The company reported a tax-prepared profit reduction of RMB 11.47 million due to asset impairment provisions for the first three quarters of 2025 [14][19]. - The company also reported a tax-prepared profit reduction of RMB 15.68 million due to credit impairment losses for the same period [16][19]. - The cash dividend distribution plan involves a payout of RMB 2 per 10 shares, totaling RMB 114.83 million (including tax) [5][6]. Business Development - The company is focusing on expanding its traditional Chinese medicine business, particularly in the areas of food and medicine integration, formula granules, and national standard products [7]. - The first centralized healthcare center has achieved breakeven within two years, and a second center is under construction, expected to open in the first half of 2026 [8]. - The company has revamped 805 stores in its non-pharmaceutical business segment, which includes health foods, medical devices, and wellness products, contributing significantly to overall performance growth [10].